Best of the Week
Most Popular
1. Market Decline Will Lead To Pension Collapse, USD Devaluation, And NWO - Raymond_Matison
2.Uber’s Nightmare Has Just Started - Stephen_McBride
3.Stock Market Crash Black Swan Event Set Up Sept 12th? - Brad_Gudgeon
4.GDow Stock Market Trend Forecast Update - Nadeem_Walayat
5.Gold Significant Correction Has Started - Clive_Maund
6.British Pound GBP vs Brexit Chaos Timeline - Nadeem_Walayat
7.Cameco Crash, Uranium Sector Won’t Catch a break - Richard_Mills
8.Recession 2020 Forecast : The New Risks & New Profits Of A Grand Experiment - Dan_Amerman
9.Gold When Global Insanity Prevails - Michael Ballanger
10.UK General Election Forecast 2019 - Betting Market Odds - Nadeem_Walayat
Last 7 days
You Should Be Buying Gold Stocks Now - 6th Dec 19
The End of Apple Has Begun - 6th Dec 19
How Much Crude Oil Do You Unknowingly Eat? - 6th Dec 19
Labour vs Tory Manifesto Voter Bribes Impact on UK General Election Forecast - 6th Dec 19
Gold Price Forecast – Has the Recovery Finished? - 6th Dec 19
Precious Metals Ratio Charts - 6th Dec 19
Climate Emergency vs Labour Tree Felling Councils Reality - Sheffield General Election 2019 - 6th Dec 19
What Fake UK Unemployment Statistics Predict for General Election Result 2019 - 6th Dec 19
What UK CPI, RPI and REAL INFLATION Predict for General Election Result 2019 - 5th Dec 19
Supply Crunch Coming as Silver Miners Scale Back - 5th Dec 19
Gold Will Not Surpass Its 1980 Peak - 5th Dec 19
UK House Prices Most Accurate Predictor of UK General Elections - 2019 - 5th Dec 19
7 Year Cycles Can Be Powerful And Gold Just Started One - 5th Dec 19
Lib Dems Winning Election Leaflets War Against Labour - Sheffield Hallam 2019 - 5th Dec 19
Do you like to venture out? Test yourself and see what we propose for you - 5th Dec 19
Great Ways To Make Money Over Time - 5th Dec 19
Calculating Your Personal Cost If Stock, Bond and House Prices Return To Average - 4th Dec 19
Will Labour Government Plant More Tree's than Council's Like Sheffield Fell? - 4th Dec 19
What the UK Economy GDP Growth Rate Predicts for General Election 2019 - 4th Dec 19
Gold, Silver and Stock Market Big Picture: Seat Belts Tightened - 4th Dec 19
Online Presence: What You Need to Know About What Others Know About You - 4th Dec 19
New Company Tip: How To Turn Prospects into Customers with CRM Tech - 4th Dec 19
About To Relive The 2007 US Housing Market Real Estate Crash Again? - 3rd Dec 19
How Far Will Gold Reach Before the Upcoming Reversal? - 3rd Dec 19
Is The Current Stock Market Rally A True Valuation Rally or Euphoria? - 3rd Dec 19
Why Shale Oil Not Viable at $45WTI Anymore, OPEC Can Dictate Price Again - 3rd Dec 19
Lib Dem Election Dodgy Leaflets - Sheffield Hallam Battle General Election 2019 - 3rd Dec 19
Land Rover Discovery Sport Brake Pads Uneven Wear Dash Warning Message at 2mm Mark - 3rd Dec 19
The Rise and Evolution of Bitcoin - 3rd Dec 19
Virtual games and sport, which has one related to the other - 3rd Dec 19
The Narrative About Gold is Changing Again - 2nd Dec 19
Stock Market Liquidity & Volume Diminish – What Next? - 2nd Dec 19
A Complete Guide To Finding The Best CFD Broker - 2nd Dec 19
See You On The Dark Side Of The Moon - 2nd Dec 19
Will Lib Dems Win Sheffield Hallam From Labour? General Election 2019 - 2nd Dec 19
Stock Market Where Are We?  - 1st Dec 19
Will Labour's Insane Manifesto Spending Plans Bankrupt Britain? - 1st Dec 19
Labour vs Tory Manifesto Debt Fuelled Voter Bribes Impact on UK General Election - 30th Nov 19
Growing Inequality Unrest Threatens Mining Industry - 30th Nov 19
Conspiracy Theories Are Killing This Nation - 30th Nov 19
How to Clip a Budgies / Parakeets Wings, Cut / Trim Bird's Flight Feathers - 30th Nov 19
Hidden Failure of SIFI Banks - 29th Nov 19
Use the “Ferrari Pattern” to Predictably Make 431% with IPOs - 29th Nov 19
Tax-Loss Selling Drives Down Gold and Silver Junior Stock Prices - 29th Nov 19
We Are on the Brink of the Second Great Depression - 29th Nov 19
How to Spot REAL Amazon Black Friday Bargains and Avoid FAKE Sales - 29th Nov 19

Market Oracle FREE Newsletter

UK House prices predicting general election result

How to Spot the Next Hot Biotech Stock

Companies / BioTech Jun 13, 2012 - 01:39 AM GMT

By: Money_Morning

Companies

Best Financial Markets Analysis ArticleKeith Fitz-Gerald writes: It's not enough to understand long- term trends, today's investors need to have the ability to move quickly, especially when it comes to biotech stocks.

But here is what you need to know about biotech stocks: none of them are created equal.


For all their potential, bio tech stocks remain among the most challenging for investors like you to identify, select and earn money on.

However, with a little bit of the right guidance you can narrow your list to the stocks with the highest likely upside.

In fact, I've developed a five- point checklist of what I look at when screening biotech stocks that I'd like to share with you.

It may not be a road map. The biotech sector just isn't that easy and "x" almost never marks the spot.

But it is a great place to start if you are serious about separating the pretenders from the contenders.

Five Steps for Successful Biotech Stock Investors
As you begin to break down a potential stock consider the following as it relates to your decision.

1) Choose your niche.
Biotech is a big term and an even bigger sector. There are literally thousands of companies trying to make their move in everything from vaccines to nano-technology.

There's quite literally no way you can know everything, so stick to the parts of the sector you believe have the biggest potential.

For instance, I think some of the biggest innovations and profits will come from bio tech companies that link living systems with their digital counterparts.

So I tend to concentrate my biotech investments in companies that are exploring synthetic biology and computational bioinformatics.

To me it's a no brainer.

While there is no question that traditional bio tech will be big, over the next few years we will see the line blur very rapidly between what we need to live and how we actually live - aided by technology.

Admittedly, I have a rather selfish reason...

Alzheimer's runs in my family so in a way I'm chasing my own gremlins. You may or may not be chasing yours.

Point is, choose a niche you have an interest in and learn everything you can about it.

2) Stick to companies with the "right" kind of debt.
This one is tricky because obviously debt is a loaded word right now. With governments spending trillions on completely misguided bailouts, it's easy to forget that debt can also be used to generate profits, particularly in early stage companies.

When you think about it this makes sense.

The average medical tech company, for example, now spends tens of millions simply getting their drug ready for laboratory testing. Add to that millions more in human trials where maybe - just maybe - the drug will be approved.

Then there is the time. Often times the process takes a decade or more after the initial development.

As onerous as this sounds, keep in mind that it's against a revenue stream that could literally be in the billions. Come up with a blockbuster, and you can be in fat city for years.

What's a blockbuster? I define that as a drug or technology that could potentially generate sales in excess of a billion dollars a year.

But back to the debt. What you want to see in a biotech company is steady funding.

Conversely, companies that attract an initial investment then burn quickly through it without being able to gather more funding are one shot wonders. With companies like that you might as well go to Vegas.

But if the debt comes as part of an overall set of progress payments in exchange for specific developmental milestones, that's a very different case indeed.

Take MicroMet for instance. It's a story about what can happen when a bidding war develops around progressive developmental payments for a promising group of therapies---in this case cancer immunotherapies.

Amgen (Nasdaq: AMGN) ultimately swallowed MicroMet for $1.16 billion, handing investor s the opportunity to capture 61.83% in the process. I know, because my readers were among them.

3) Understand that volatility is part of the package.
Just like debt, understand that there is good volatility and bad volatility.

Biotech companies with bad volatility tend to move wildly yet are still generally correlated to the markets. This suggests that they really don't have too much going for them.

The true winners often move independently of broader market conditions. Not always mind you, but enough that you can screen for a kind of "anti-correlation" for lack of a better term.

This can be hard to do because many promising bio-tech companies have very small market capitalizations and even smaller daily trading volume.

It means you need to look behind the numbers to see if you can account for the price swings. Are insiders buying or selling? Or, has an institution stepped up with the sort of payment "plan" investment I've just referenced?

Many times the big pharma companies will set up a series of structured investments that keep them off the radar while simultaneously keeping values low enough to represent a solid risk/reward ratio.

Their thinking is sound. After all, why tip off the markets when that makes a sweetheart deal more expensive for them?

Be cognizant of the story behind the story.

4) Spread your risks.
Bio tech investors need to recognize that the odds are stacked against them from the get go. While that doesn't necessarily mean you will lose, the odds of winning depend on carefully placing your bets and maintaining an adequate book.

You really can't adequately play unless you're willing to put at least $5,000 on the table and be comfortable with the idea you may lose 90% of it before one of the choices you make pays off.

Michael Milken of Drexel Burnham Lambert famously used to use this strategy back in the late 1980s with junk bonds. He'd buy 100 of them knowing full well that 98% would blow up and that the 1-2% that hit would hit so big he could laugh all the way to the bank.

His compensation was more than $1 billion in a four year period-- - a new record at the time according to the NY Times.

It's worth noting that he had only four losing months in 17 years spent trading.

Today he's heavily involved in medical research presumably for the same reasons we are...because they hold great promise.

5) Look for the Jolly Roger
Recent venture capitalist estimates suggest that life sciences investments may fall to only $2.5 billion in 2012. This is because many VC funding sources have been burned over the past few years.

Instead of crying me a river, you can use that to your advantage.

VC firms are like a bunch of modern pirates in that they go where the money is. That's why you want to figure out where they've hoisted the financial equivalent of a "Jolly Roger."

Right now buyouts are hot. Limited partners--a.k.a venture capitalists--won't take on new investments unless they see a path to liquidity in five years or less. That includes a buyout by a major pharma or tech company or a licensing deal from one of the same.

In other words, VC firms want to identify their exit strategy before they take a stake and put up the funding.

It only stands to reason that if you can tie a specific VC to the areas in which you are interested in and even more specifically to a particular company then you've got a good shot at a picking a winner.

As for IPOs, they are not the magic ticket they used to be. In the wake of the botched Facebook IPO, the public has only learned to distrust the process.

At the end of the day though, for all its difficulties, investing in biotech can be one of the single biggest roads to profitability.

Just make sure you've got an idea where you're headed and a rock solid grasp on risk management.
The last thing you want to do is blow your money on a promise that really isn't there.

Source :http://moneymorning.com/2012/06/12/5-ways-to-spot-the-next-hot-biotech-stock/

Money Morning/The Money Map Report

©2011 Monument Street Publishing. All Rights Reserved. Protected by copyright laws of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), of content from this website, in whole or in part, is strictly prohibited without the express written permission of Monument Street Publishing. 105 West Monument Street, Baltimore MD 21201, Email: customerservice@moneymorning.com

Disclaimer: Nothing published by Money Morning should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investent advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication, or after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Money Morning should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Money Morning Archive

© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules